Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
Scand J Rheumatol. 2005 Sep-Oct;34(5):353-8. doi: 10.1080/03009740510026887.
Scand J Rheumatol. 2005.
PMID: 16234182